We provide end-to-end biologics CDMO support aligned to Pharmaceutical Development & Manufacturing → Drug Substance Development → Cytokine Development. Within this framework, our interferon programs emphasize robust laboratory biotechnology, platformable processes, and analytics designed for seamless advancement.
Overview of Interferon Development
Interferons are small, structurally sensitive cytokines whose bioactivity depends on precise folding, controlled aggregation, and, for selected subtypes, appropriate glycosylation. Successful development hinges on expression-system strategy, refolding or secretion control, purification selectivity, and potency methods calibrated to international units. Because interferons can oxidize, deamidate, or dimerize under stress, early stability modeling, excipient screening, and orthogonal characterization are essential. We deploy platformable upstream and downstream approaches, qualified reference standards, and mechanism-reflective bioassays to generate consistent materials across research scales.
Our Services
The portfolio spans upstream design, purification platforms, analytical sciences, and bioassay development—each modular yet tightly connected for interferon-specific needs.
Upstream Development Service
We select and optimize expression systems tailored to interferon subtype and quality targets. For non-glycosylated formats, bacterial hosts with controlled inclusion-body formation can maximize yield while preserving refoldability. For glycosylated interferons, mammalian systems enable N-linked glycan maturation and secretion.
Refolding and Secretion Control Service
For E. coli routes, we deploy empiric and design-of-experiments refolding screens to define redox couples, denaturant gradients, and protein concentration windows that minimize off-pathway aggregation. For secreted processes, we tune signal peptides, temperature shifts, and chaperone leverage to promote correct disulfide pairing.
Purification Service
We construct selective, minimal-step schemes around cation/anion exchange, mixed-mode, and hydrophobic interaction or reverse-phase polishing, depending on subtype and impurity profile. Strategies address host-cell proteins, misfolded species, multimers, endotoxin (where applicable), and residual DNA. We define clearance factors for each unit operation and build a coherent control strategy linking column chemistry, load density, conductivity/pH windows, and gradient shape to target purity and potency.
Analytical Characterization Service
We design interferon-specific method panels that are orthogonal and stability-indicating. Typical suites include intact and peptide-map LC–MS for sequence confirmation and PTMs (oxidation, deamidation), icIEF or cation-exchange for charge variants, SEC-HPLC/UPLC with light scattering for aggregation, and RP-HPLC for hydrophobic variants.
Bioassay Development and Potency Assignment Service
We establish functional, mechanism-reflective bioassays aligned to interferon signaling, typically via reporter-gene or antiviral surrogate systems, with statistical designs supporting linearity, parallelism, and relative potency. We calibrate to international or in-house reference standards to express results in IU or defined activity units.
We provide specialized CDMO development for interferons spanning upstream, purification, analytics, and bioassays. Our platformable methods, reference standards, and comparability frameworks streamline R&D and prepare programs for efficient downstream decisions. Contact us to initiate a tailored plan.
Frequently Asked Questions
Q1: How do you decide between bacterial and mammalian expression for interferons?
We align the host to the target quality profile. Non-glycosylated formats often benefit from high-yield bacterial expression with well-controlled refolding to achieve native disulfide patterns. Glycosylated formats (certain IFN-β and lambda species) typically require mammalian secretion to realize desired glycan attributes, which can influence charge variants, solubility, and stability. We prototype both routes when trade-offs are uncertain and select based on potency, heterogeneity, and manufacturability.
Q2: What are the key analytical methods for interferon heterogeneity and stability?
We combine intact and peptide-mapping LC–MS for sequence/PTMs, icIEF or cation-exchange for charge isoforms, SEC with light scattering for aggregates, and RP-HPLC for hydrophobic variants. Oxidation (e.g., methionine), deamidation, dimerization, and truncations are monitored as stability-indicating markers. Binding surrogates and bioassays provide functional anchors, ensuring analytical changes correlate with activity.
Q3: How do you mitigate aggregation and oxidation during development?
We integrate process and formulation levers: redox-guided refolding or secretion optimization, purification steps that remove misfolded/oxidized species, and excipient screens identifying buffers, surfactants, and antioxidants that reduce interfacial and chemical stress. Stress studies (agitation, light, thermal) inform design spaces and establish acceptance criteria for aggregates and oxidative variants.
Our products and services are for research use only.
